The 2023 Autumn Focus workshop focusses on industry’s challenge of the current paradigm for ADA testing and includes insights and recommendations on lean approaches for first clinical studies (based on risk) and experience /case studies related to diversity of biotherapeutics portfolios (i.e. drug tolerance, multidomain therapeutics…)
The agenda will be built considering case studies and (project/regulatory) experience from the EBF community and presentations from a call for abstract which will be launched mid-February 2023 (deadline for abstract submission: 31 May 2023). Meeting attendance will be limited to 80 delegates.
Meeting attendance will be limited to 80 delegates with a maximum of 4 delegates/company.